The largest prospective warfarin-treated cohort supports genetic forecasting
Top Cited Papers
Open Access
- 22 January 2009
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 113 (4) , 784-792
- https://doi.org/10.1182/blood-2008-04-149070
Abstract
Genetic variants of cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) are known to influence warfarin dose, but the effect of othKeywords
This publication has 52 references indexed in Scilit:
- Genotypes of vitamin K epoxide reductase, γ-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patientsThrombosis Research, 2007
- Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral AnticoagulationCirculation, 2007
- Pharmacogenetics of warfarin: regulatory, scientific, and clinical issuesJournal of Thrombosis and Thrombolysis, 2007
- Influence of CYP2C9 and VKORC1 1173C/T Genotype on the Risk of Hemorrhagic Complications in African-American and European-American Patients on WarfarinClinical Pharmacology & Therapeutics, 2007
- Association of warfarin dose with genes involved in its action and metabolismHuman Genetics, 2006
- Effect ofVKORC1Haplotypes on Transcriptional Regulation and Warfarin DoseNew England Journal of Medicine, 2005
- Internet based clinical trial protocols – as applied to a study of warfarin pharmacogeneticsBritish Journal of Clinical Pharmacology, 2004
- Haploview: analysis and visualization of LD and haplotype mapsBioinformatics, 2004
- Pedigree disequilibrium tests for multilocus haplotypesGenetic Epidemiology, 2003
- Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complicationsThe Lancet, 1999